Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

被引:1
作者
Zhang, Huiyuan [1 ]
Meng, Xiangxi [2 ]
Wang, Zhe [3 ]
Zhou, Xin [2 ]
Liu, Yang [2 ]
Li, Nan [2 ]
机构
[1] Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Nucl Med, Beijing 101149, Peoples R China
[2] Peking Univ, Minist Educ, Dept Nucl Med, Natl Med Prod Adm,Canc Hosp & Inst,Beijing Key Lab, 52 Fucheng Rd, Beijing 100142, Peoples R China
[3] Cent Res Inst, United Imaging Healthcare Grp, Shanghai 201900, Peoples R China
关键词
PD-L1; F-18] FDG; PET/CT; radiomics; lung adenocarcinoma; POSITRON-EMISSION-TOMOGRAPHY; CANCER; EXPRESSION; DOCETAXEL; INFORMATION; NIVOLUMAB; IMAGES;
D O I
10.3390/diagnostics15050543
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: This study aims to retrospectively analyze the clinical and imaging data of 101 patients with lung adenocarcinoma who underwent [F-18]FDG PET/CT examination and were pathologically confirmed in the Department of Nuclear Medicine at Peking University Cancer Hospital. This study explores the predictive value and important features of [F-18]FDG PET/CT radiomics for PD-L1 expression levels in lung adenocarcinoma patients, assisting in screening patients who may benefit from immunotherapy. Methods: 101 patients with histologically confirmed lung adenocarcinoma who received pre-treatment [F-18] FDG PET/CT were included. Among them, 44 patients were determined to be PD-L1 positive and 57 patients were determined to be PD-L1 negative based on immunohistochemical assays. Clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics were included in the modeling. Random Forest was used in feature denoising, while Forward Stepwise Regression and the Least Absolute Shrinkage and Selection Operator were used in feature selection. Models based on Tree, Discriminant, Logistic Regression, and Support Vector Machine were trained and evaluatedto explore the value of clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics. Results: All models showed some predictive ability in distinguishing PD-L1 positive from PD-L1 negative samples. Among the multimodal imaging, clinical data were incorporated into the models, with clinical stage and gender selected by Forward Stepwise Regression, while clinical stage, smoking history, and gender were selected by LASSO. When incorporating clinical data and thin-section CT-derived images into the models, nodular type, spiculation, and CT Shape Flatness were selected by Forward Stepwise Regression, while nodular type and spiculation were selected by LASSO. When incorporating clinical data, PET/CT radiomics, observed CT characteristics, and conventional metabolic information. Forward Stepwise Regression selected TLGlean, MTV, nodule component, PET Shape Sphericity, while LASSO selected SULmax, MTV, nodular type, PET Shape Sphericity, and spiculation. Conclusions: The integration of clinical data, PET/CT radiomics, and conventional metabolic parameters effectively predicted PD-L1 expression, thereby assisting the selection of patients who would benefit from immunotherapy. Observed CT characteristics and conventional metabolic information play an important role in predicting PD-L1 expression levels.
引用
收藏
页数:13
相关论文
共 28 条
[1]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[2]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[3]   Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial [J].
Cascone, Tina ;
William, William N., Jr. ;
Weissferdt, Annikka ;
Leung, Cheuk H. ;
Lin, Heather Y. ;
Pataer, Apar ;
Godoy, Myrna C. B. ;
Carter, Brett W. ;
Federico, Lorenzo ;
Reuben, Alexandre ;
Khan, Md Abdul Wadud ;
Dejima, Hitoshi ;
Francisco-Cruz, Alejandro ;
Parra, Edwin R. ;
Solis, Luisa M. ;
Fujimoto, Junya ;
Tran, Hai T. ;
Kalhor, Neda ;
Fossella, Frank V. ;
Mott, Frank E. ;
Tsao, Anne S. ;
Blumenschein, George, Jr. ;
Le, Xiuning ;
Zhang, Jianjun ;
Skoulidis, Ferdinandos ;
Kurie, Jonathan M. ;
Altan, Mehmet ;
Lu, Charles ;
Glisson, Bonnie S. ;
Byers, Lauren Averett ;
Elamin, Yasir Y. ;
Mehran, Reza J. ;
Rice, David C. ;
Walsh, Garrett L. ;
Hofstetter, Wayne L. ;
Roth, Jack A. ;
Antonoff, Mara B. ;
Kadara, Humam ;
Haymaker, Cara ;
Bernatchez, Chantale ;
Ajami, Nadim J. ;
Jenq, Robert R. ;
Sharma, Padmanee ;
Allison, James P. ;
Futreal, Andrew ;
Wargo, Jennifer A. ;
Wistuba, Ignacio I. ;
Swisher, Stephen G. ;
Lee, J. Jack ;
Gibbons, Don L. .
NATURE MEDICINE, 2021, 27 (03) :504-+
[4]   PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT [J].
Cui, Yan ;
Li, Xuena ;
Du, Bulin ;
Diao, Yao ;
Li, Yaming .
CANCER MANAGEMENT AND RESEARCH, 2020, 12 :6385-6395
[5]   Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer [J].
Fehrenbacher, Louis ;
von Pawel, Joachim ;
Park, Keunchil ;
Rittmeyer, Achim ;
Gandara, David R. ;
Aix, Santiago Ponce ;
Han, Ji-Youn ;
Gadgeel, Shirish M. ;
Hida, Toyoaki ;
Cortinovis, Diego L. ;
Cobo, Manuel ;
Kowalski, Dariusz M. ;
De Marinis, Filippo ;
Gandhi, Mayank ;
Danner, Bradford ;
Matheny, Christina ;
Kowanetz, Marcin ;
He, Pei ;
Felizzi, Federico ;
Patel, Hina ;
Sandler, Alan ;
Ballinger, Marcus ;
Barlesi, Fabrice .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1156-1170
[6]   Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].
Fehrenbacher, Louis ;
Spira, Alexander ;
Ballinger, Marcus ;
Kowanetz, Marcin ;
Vansteenkiste, Johan ;
Mazieres, Julien ;
Park, Keunchil ;
Smith, David ;
Artal-Cortes, Angel ;
Lewanski, Conrad ;
Braiteh, Fadi ;
Waterkamp, Daniel ;
He, Pei ;
Zou, Wei ;
Chen, Daniel S. ;
Yi, Jing ;
Sandler, Alan ;
Rittmeyer, Achim .
LANCET, 2016, 387 (10030) :1837-1846
[7]   Neoadjuvant PD-1 Blockade in Resectable Lung Cancer [J].
Forde, P. M. ;
Chaft, J. E. ;
Smith, K. N. ;
Anagnostou, V. ;
Cottrell, T. R. ;
Hellmann, M. D. ;
Zahurak, M. ;
Yang, S. C. ;
Jones, D. R. ;
Broderick, S. ;
Battafarano, R. J. ;
Velez, M. J. ;
Rekhtman, N. ;
Olah, Z. ;
Naidoo, J. ;
Marrone, K. A. ;
Verde, F. ;
Guo, H. ;
Zhang, J. ;
Caushi, J. X. ;
Chan, H. Y. ;
Sidhom, J. -W. ;
Scharpf, R. B. ;
White, J. ;
Gabrielson, E. ;
Wang, H. ;
Rosner, G. L. ;
Rusch, V. ;
Wolchok, J. D. ;
Merghoub, T. ;
Taube, J. M. ;
Velculescu, V. E. ;
Topalian, S. L. ;
Brahmer, J. R. ;
Pardoll, D. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) :1976-1986
[8]   Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer [J].
He, Jiabei ;
Hu, Ying ;
Hu, Mingming ;
Li, Baolan .
SCIENTIFIC REPORTS, 2015, 5
[9]   Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].
Herbst, Roy S. ;
Baas, Paul ;
Kim, Dong-Wan ;
Felip, Enriqueta ;
Perez-Gracia, Jose L. ;
Han, Ji-Youn ;
Molina, Julian ;
Kim, Joo-Hang ;
Arvis, Catherine Dubos ;
Ahn, Myung-Ju ;
Majem, Margarita ;
Fidler, Mary J. ;
de Castro, Gilberto, Jr. ;
Garrido, Marcelo ;
Lubiniecki, Gregory M. ;
Shentu, Yue ;
Im, Ellie ;
Dolled-Filhart, Marisa ;
Garon, Edward B. .
LANCET, 2016, 387 (10027) :1540-1550
[10]   Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result [J].
Jiang, Mengmeng ;
Sun, Dazhen ;
Guo, Yinglong ;
Guo, Yixian ;
Xiao, Jie ;
Wang, Lisheng ;
Yao, Xiuzhong .
ACADEMIC RADIOLOGY, 2020, 27 (02) :171-179